共 163 条
[1]
Herbst RS(2008)Lung Cancer N Engl J Med 359 1367-1380
[2]
Heymach JV(2008)Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries Jpn J Clin Oncol 38 641-648
[3]
Lippman SM(1995)Lung Cancer Cancer 75 191-202
[4]
Matsuda T(2010)Gefitinib of chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[5]
Marugame T(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[6]
Kamo K(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-742
[7]
Katanoda K(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-246
[8]
Ajiki W(2013)Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 3327-3334
[9]
Sobue T(2005)EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786-792
[10]
Travis WD(2005)Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73-2247